Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study

PURPOSE: RBP-7000 (PERSERIS™) is a once-monthly subcutaneous extended-release risperidone formulation approved by the United States Food and Drug Administration for the treatment of schizophrenia in adults. The objective of this study was to describe the long-term impact of RBP-7000 on health-relate...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhanda, Rahul, Varghese, Della, Nadipelli, Vijay R, Fava, Maurizio, Joshi, Namita, Solem, Caitlyn T, Graham, James A, Learned, Susan M, Heidbreder, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612993/
https://www.ncbi.nlm.nih.gov/pubmed/31308636
http://dx.doi.org/10.2147/PPA.S202173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612993/
https://www.ncbi.nlm.nih.gov/pubmed/31308636
http://dx.doi.org/10.2147/PPA.S202173

Ejemplares similares